Diurnal Share Discussion Threads

[l0ngterm] 13/11/2020 00:01

Well it will be interesting to see what happens. As wee have Nasdaq companies applauding the companies products and sales potential. Hmm But this is Aim, and strange times. gla

[cyberbub] 12/11/2020 23:53

That all sounds very encouraging... Let's see the share price reaction tomorrow!

[l0ngterm] 12/11/2020 21:54

Thanks for sharing this folks.

[parc1] 12/11/2020 21:45

Eton Pharmaceuticals Webcast 21:30 GMT 12 November 2020

" Turning now to our lead product Alkindi.. we have been inundated by enquiries from paediatric endocrinologists and how they are very excited to get their hands on Alkindi Sprinkle.

We are pleased to announce that we expect to have the product available before the end of the month.

The sales reps were released October 23rd and already have held or scheduled meetings with 120 of the 800 endocrinologists in the US. The feedback from those meetings has been overwhelmingly positive and we expect the patients to be enrolled immediately once the product becomes available.

The launch of Alkindi will be transformational for the company... The Alkindi opportunity sets us up for a major 2021.

Alkindi launch weeks away.

Up to 10,000 patients in US. mg basis pricing. Believe there will be a quick ramp up towards the $100 million+ market.

Endocrinology has not really been affected by pandemic and still have remote appointments.

The real growth driver is Alkindi. "

[bad gateway] 12/11/2020 21:36

They're being inundated with calls for sprinkle and expect it to be transformational for eton,
Webcast link

[l0ngterm] 12/11/2020 21:21

They turned that around quickly, so milestone payment for DNL and official start of sales in the US. All good :-)

[bad gateway] 12/11/2020 21:14

ETON update re sprinkle..

“In recent weeks we submitted the last of our nine product candidates to the FDA. This is a tremendous accomplishment by our team after years of hard work. We are now turning our focus to building out a leading orphan drug commercial organization,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “Early interest in ALKINDI SPRINKLE from physicians and caregivers has been very strong and has reiterated the significant need for the product.”


Recent Business Milestones

FDA approval of orphan product ALKINDI® SPRINKLE. In September, ALKINDI SPRINKLE was approved by the FDA as a replacement therapy for Adrenocortical Insufficiency in patients under 17 years of age. Eton expects to have the product commercially available by the end of November.

FDA approval of Alaway Preservative Free®. During the quarter, Alaway Preservative Free was approved by the FDA. Bausch Health plans to launch the product by the Spring of 2021 and Eton will receive a royalty on sales of the product.

Four additional NDAs submitted to the FDA. Eton, or its partners, have submitted four NDAs in the second half of 2020. Dehydrated alcohol injection, zonisamide oral suspension, and ephedrine injection have all been accepted for filing and assigned PDUFA dates of May 27, 2021; May 29, 2021; and June 18, 2021, respectively.

Successful completion of equity financing. In October, Eton closed an oversubscribed common stock offering which resulted in gross proceeds of approximately $22.5 million. The proceeds are expected to be sufficient to allow Eton to launch its current pipeline products and reach profitability.

ALKINDI SPRINKLE

Eton anticipates having commercial availability of ALKINDI SPRINKLE by the end of November. The company’s ALKINDI SPRINKLE sales representatives have been hired, fully trained, and have begun engaging with pediatric endocrinologists. Initial interest from physicians, caregivers, and patients has been very strong and Eton expects the product to exceed the company’s original sales forecast for 2021

[aimmafia] 12/11/2020 17:19

Who would of thought people buy and sell

[scrabster1] 12/11/2020 14:24

Selling and buying huh, that old trick ?! Lol

[s34icknote] 11/11/2020 21:57

Peeps selling and buying moving stocks making this fall

[hennes ix] 11/11/2020 16:01

still in still here, but can't understand the price development ... now nearly 10 per cent under the capital raising quote ... who is selling ahead of good news and the bet on possible approval Chronocort Q1 2021?

[vikingwarrier] 11/11/2020 11:45

Hope tomorrow sees a bit of action here.

[dandu69] 11/11/2020 11:05

can buy on Halifax at the moment no problem at 54.9 for 20k.

[scrabster1] 11/11/2020 10:49

Not seen anything this illiquid in a while !

[bad gateway] 11/11/2020 09:36

Can buy on IG but they want 54.75 for 10k shares, over 55 for 20k.

[cottoner] 11/11/2020 09:28

Haven't been able to get a quote to buy via Halifax all morning.

Other platforms giving quotes?

[bad gateway] 11/11/2020 09:26

Don't disagree on the chart the trend has been a bit relentless but do have to watch we don't get caught out by the doublebottom here imo. This level was the low early Sept and the stock jumped sharply.
With the selling seemingly abated and news from eton tomorrow might be a change of tide?

[dandu69] 11/11/2020 09:17

The optimistic side is willing to rise but looking at the chart the opposite looks more likely. May get more interest tomorrow PM after Eton results?

[aimmafia] 11/11/2020 08:59

I dont understand you. One minute youre talking about it going up, then youre talking about 48p

[dandu69] 11/11/2020 05:21

agree on that best, so much for 60p area being a floor for the price. The chart not looking good for the short term, looking to add around 48p if it drops this low.

[best1467] 10/11/2020 20:10

Valuation just getting Crazier by the day £74 million M Cap with what’s been achieved and in the last 12 months is Madness.
While it’s frustrating i will start to add to an already considerable holding value is always rewarded eventually the lower it goes the better the investment for anyone with a medium to long term view IMHO

[bad gateway] 10/11/2020 16:14

Might be interesting for Thursday.


November 04, 2020 16:05 ET | Source: Eton Pharmaceuticals
DEER PARK, Ill., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it will report third quarter 2020 financial and operating results on Thursday, November 12, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (3:30 p.m. CT).

The live webcast can be accessed on the investors section of Eton’s website at The conference call can be accessed by dialing 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 5092872. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.

About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases. The company currently owns or receives royalties from three FDA-approved approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway® Preservative Free, and has six additional products in its late-stage pipeline, including five that have been submitted to the FDA.

[bad gateway] 10/11/2020 13:29

Still got my shares too just didn't go my way on the short term trade is all.
Will probs bounce now. lol

[dandu69] 10/11/2020 13:19

likewise longterm......

[l0ngterm] 10/11/2020 13:16

Fair call Dandu, overall as long as nothing fundamentally changes with the company then happy to hold. GLA